You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Autism Treatment The Pivotal Skills Trainer

    SBC: ACCELERATIONS EDUCATIONAL SOFTWARE            Topic: N/A

    DESCRIPTION (provided by applicant): This STTR (Phase 1) project begins the translation of untapped scientific findings into an improved software tool for teaching children with autism spectrum disorders and other disabilities. The project evaluates a package to train teachers to use software called the Pivotal Skills Trainer and examines whether doing so improves preschoolers' functional communic ...

    STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health
  2. Autism Education and Treatment with PowerPoint Software

    SBC: ACCELERATIONS EDUCATIONAL SOFTWARE            Topic: N/A

    DESCRIPTION (provided by applicant): PowerPoint(R) multimedia software is ubiquitous in our schools but its capacity for teaching children with autism spectrum and related disorders barely has been realized. This STTR (Phase I) project will begin to change this state of affairs by researching and developing empirically derived multimedia teaching tools. Encouraged by early-stage feasibility work, ...

    STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health
  3. NET- Selective Ligands for the Treatment of Depression

    SBC: Acenta Discovery, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): World-wide public health surveys point to an increased global health burden for serious psychiatric disorders, particularly depression. Indeed, by 2020 it is expected that depression may be the second most serious medical condition with respect to global disease burden. It is clear that more effective pharmacotherapies are needed in treating depressive illn ...

    STTR Phase I 2003 Department of Health and Human ServicesNational Institutes of Health
  4. Akt Inhibitors to Treat Ewing's Sarcoma

    SBC: Acenta Discovery, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): Novel drugs that improve overall survival with decreased morbidity are critical in the war on cancer. Acenta Discovery Inc. has partnered with the Toretsky Lab of the Lombardi Cancer Center to create and preclinically evaluate novel inhibitors of the protein Akt. An Akt inhibitor would have tremendous value in improving the lives of patients with many types ...

    STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health
  5. Caspase Inhibitor for Neuroprotection

    SBC: Acenta Discovery, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): An important role for apoptosis has been established in various pathological processes, particularly in nervous tissues. Apoptosis essentially contributes to neuronal loss during normal development, after acute neuronal injury, and in chronic degenerative conditions such as Alzheimer's disease, Huntington's disease, Parkinson's disease, and amyotrophic lateral ...

    STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health
  6. Development of NET-Selective Piperidine-Based PET Ligand

    SBC: Acenta Discovery, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): World-wide public health surveys point to an increasing global health burden resulting from serious brain disorders, particularly mood-related disorders such as depression. The economic burden of depression alone is immense. Of the $83.1 billion spent in 2000 on the treatment of depression and related expenses, $26.1 billion (31 percent) were direct medical cos ...

    STTR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  7. Novel Inhibitors of Pim Protein Kinases

    SBC: VORTEX BIOTECHNOLOGY CORPORATION            Topic: N/A

    DESCRIPTION (provided by applicant): There is a growing body of evidence that implicates the protein kinase Pim-1 as a major driver of prostate cancer progression, and perhaps response to chemotherapy. Pim-1 is overexpressed in early prostate intraepithelial neoplasia and metastatic prostate cancer, and its levels predict response to therapy. Pim-1-overexpressing mouse prostate stem cells demonstr ...

    STTR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  8. BROAD SPECTRUM BETA-LACTAMASE INHIBITORS

    SBC: ALAMX, LLC            Topic: N/A

    DESCRIPTION (Adapted from the application): Penicillin-resistant bacteria pose a serious threat to human welfare. This project will generate new products designed to defeat resistant microorganisms. The most prevalent cause of bacterial resistance involves the destruction of the antibiotic with the enzyme B-lactamase. There are more than 255 known B-lactamases, whi ...

    STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health
  9. NON-NATURAL AMINO ACIDS IN PEPTIDE DRUG DEVELOPMENT

    SBC: ARGOLYN BIOSCIENCE, INC.            Topic: N/A

    Argolyn Bioscience Inc. is an early stage biotechnology company that creates novel peptide drugs and diagnostics with greatly improved intrinsic pharmaceutical properties through substitution of non-natural amino acid analogues for arginine (Arg) or lysine (Lys). In proof-of concept studies thus far, application of the Argolyn technology to peptides of therapeutic interest has resulted in dramatic ...

    STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health
  10. NOVEL NEUROTENSIN ANALOGS AS ANTISCHIZOPRENICS

    SBC: ARGOLYN BIOSCIENCE, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The brain peptide neurotensin (NT) and its active derivative NT [8-13] function as endogenous neuroleptics. Stable NT derivatives that cross the blood brain barrier therefore have significant potential for development as a new class of non-dopamineric antipsychotics expected not to display the adverse side effects associated with the dopaminergics. The best lit ...

    STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government